First Approval For Kolon's Invossa But No Disease-Modifying Status

Kolon Life Science's Invossa gets regulatory approval in South Korea as the world's first allogeneic cell-mediated gene therapy for degenerative osteoarthritis, but misses out on disease-modifying status, although the company hopes a large-scale Phase III study can rectify this in the US.